RVL Pharmaceuticals PLC (RVLPQ)
0.00
USD |
OTCM |
May 16, 16:00
RVL Pharmaceuticals SG&A Expense (Quarterly): 13.89M for June 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 13.89M |
| March 31, 2023 | 16.20M |
| December 31, 2022 | 17.60M |
| September 30, 2022 | 20.38M |
| June 30, 2022 | 20.17M |
| March 31, 2022 | 23.83M |
| December 31, 2021 | 23.69M |
| September 30, 2021 | 24.84M |
| June 30, 2021 | 21.05M |
| March 31, 2021 | 16.95M |
| December 31, 2020 | 18.80M |
| September 30, 2020 | 21.36M |
| Date | Value |
|---|---|
| June 30, 2020 | 14.34M |
| March 31, 2020 | 21.18M |
| December 31, 2019 | 21.11M |
| September 30, 2019 | 24.75M |
| June 30, 2019 | 25.51M |
| March 31, 2019 | 21.66M |
| December 31, 2018 | 22.95M |
| September 30, 2018 | 17.45M |
| June 30, 2018 | 16.68M |
| March 31, 2018 | 17.16M |
| December 31, 2017 | 15.65M |
| September 30, 2017 | 13.26M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
13.89M
Minimum
Jun 2023
25.51M
Maximum
Jun 2019
20.33M
Average
21.05M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |
| iBio Inc | 2.961M |
| Theriva Biologics Inc | 1.933M |
| Oragenics Inc | 1.754M |